References in periodicals archive ?
In March 2002, Gilead announced the initiation of an early access program in the United States to provide adefovir dipivoxil to chronic hepatitis B patients with lamivudine-resistant HBV.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide.
Tenofovir's safety profile is considerably improved over adefovir, a closely related compound developed by Gilead.
Gilead scientists are reporting almost identical preliminary results from a similar 552-person phase III treatment-intensification trial.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.
All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
For more information on Gilead, please call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235) or visit www.
Under the terms of the agreement, Gilead will provide to both IPM and CONRAD a royalty-free license to develop and, if proven efficacious, distribute tenofovir as a microbicide in approximately 100 resource-limited countries hardest hit by the HIV epidemic.
On November 17, 2006, Gilead caused one of its wholly-owned subsidiaries to be merged into Myogen.
As previously announced on October 2, 2006, Gilead and Myogen entered into a definitive merger agreement for Gilead to acquire all of the outstanding shares of common stock of Myogen for $52.
All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update any such forward-looking statements or other statements included in this press release.
Gilead and Myogen believe data from two completed pivotal Phase III studies (ARIES 1&2) evaluating the safety and efficacy of the product as a potential treatment for PAH would support a New Drug Application (NDA).